Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2023-03-16 Earnings Release
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
CS PHARMANUTRA – PHN - Approvazione progetto di Bilancio 2022
Earnings Release Classification · 1% confidence The document is a formal communication from PHARMANUTRA S.P.A. dated March 16, 2023, with the subject line 'CS PHARMANUTRA – PHN - Approvazione progetto di Bilancio 2022' (Approval of the 2022 Financial Statement Project). The text explicitly states that the Board of Directors approved the Draft Financial Statements and Consolidated Financial Statements as of December 31, 2022, and presents detailed financial results (Revenues, Gross Operating Margin, Net Result) for the year 2022 compared to 2021. This content strongly indicates the release of annual financial performance data. Although it is a press release announcing the approval, the document itself contains the core financial highlights and analysis, making it an Earnings Release (ER) or potentially an Interim/Quarterly Report (IR) if it were for a shorter period. Since it covers the full year (2022) and includes the 'Progetto di Bilancio' (Draft Financial Statement), it is most closely aligned with the comprehensive financial reporting associated with an Annual Report, but since it is presented as a communication (CS - Comunicato Stampa) and not the full 10-K filing itself, and it focuses on the *approval* and key figures, it fits best as an Earnings Release (ER) or a precursor to the full Annual Report. Given the depth of the financial tables and management commentary on the full year's performance, it is more substantial than a typical ER, but less formal than a 10-K. However, the definition for 'Annual Report (10-K)' is for the 'Official yearly report covering company activity and full financial performance.' This document is the *announcement* of the approval of that report, containing the key figures. If the document were extremely short and only announced the availability of the full report, it would be RPA. Since it contains substantial financial data and commentary on the full year, it functions as the primary release of annual results. In the context of the provided codes, 'ER' (Earnings Release) is the closest fit for the initial release of annual financial highlights and results, even though it covers the full year, as it is a press release format. If the document were the full, audited 10-K, that would be the choice. Since it is the announcement of the approved draft financials, ER is the most appropriate classification among the choices for a major financial result announcement. FY 2022
2023-03-16 Italian
PR PHARMANUTRA S.P.A. - PHN - THE STRATEGIC GUIDELINES FOR THE NEXT YEARS WERE PRESENTED AT THE INVESTOR'S DAY
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by the structure, the 'Oggetto' field mentioning 'PR PHARMANUTRA S.P.A.' and the content describing an 'Investor Day' where 'strategic guidelines for the next years were presented'). The key subject is the presentation of strategic guidelines and future prospects to the financial community/investors. This aligns best with an Investor Presentation (IP), which typically covers strategy, financials, and market position presented to investors. Although it is a press release announcing the event, the core content delivered *at* the event is the presentation material itself, making IP a strong fit. However, since this is the *announcement* of the event and the presentation materials are stated to be available on the website ('The presentation showed today to investors is available on the Investor section on the website of the company'), it could also be considered a Report Publication Announcement (RPA) if the focus was purely on the availability. Given the detailed summary of the strategic outlook and growth forecasts shared during the event, it functions as a summary of the Investor Presentation content. Since 'Investor Presentation' (IP) is defined as detailed presentation for investors focusing on financials, strategy, and market position, and this document summarizes exactly that content shared at the Investor Day, IP is the most accurate classification for the substance being communicated, even if delivered via a press release format.
2023-02-21 English
CS PHARMANUTRA SPA - PHN - ALL’INVESTOR DAY PRESENTATE LE LINEE STRATEGICHE PER I PROSSIMI ANNI
Regulatory Filings Classification · 1% confidence The document is an official communication (Informazione Regolamentata) with the subject line: 'CS PHARMANUTRA SPA - PHN - ALL'INVESTOR DAY PRESENTATE LE LINEE STRATEGICHE PER I PROSSIMI ANNI' (CS PHARMANUTRA SPA - PHN - STRATEGIC GUIDELINES FOR THE COMING YEARS PRESENTED AT THE INVESTOR DAY). The text explicitly describes an 'Investor Day' where management presented strategic horizons, growth drivers, and long-term plans to the financial community. This content aligns perfectly with the definition of an Investor Presentation (IP), which typically covers strategy, financials, and market position presented to investors. Although it is a press release announcing the event, the core content is the presentation material itself, making 'IP' the most specific classification for the information conveyed, rather than a general 'RPA' or 'ER'.
2023-02-21 Italian
Allegato 3F_Gennaio 2023
Transaction in Own Shares Classification · 1% confidence The document is a formal disclosure titled "SCHEMA DI COMUNICAZIONE DELLE OPERAZIONI SUI TITOLI DELL'EMITTENTE" (Model Disclosure for Transactions in the Issuer's Securities) submitted by Pharmanutra S.p.A. It details transactions (purchases/sales, indicated by 'A' for Acquisto/Purchase in the table) conducted by a party (INTERMONTE SPA) involving the issuer's shares during January 2023 (Reference Period 01/2023). This type of filing, reporting personal share transactions by executives or related parties, directly corresponds to the definition of Director's Dealing or Insider Trading reports. Reviewing the definitions: - 10-K/IR: Not a full annual or interim report. - ER/MRQ: Not an earnings release or major shareholding notification. - DIV/CAP/SHA: Not a dividend, financing, or general share issue announcement. - DIRS (Director's Dealing): This category covers reports of personal share transactions by company directors and executives (insider trades). Although the transacting party here is 'INTERMONTE SPA', the structure and content (transaction details on issuer's securities) strongly align with insider transaction reporting requirements, which fall under the scope of DIRS in many regulatory frameworks, especially when related to management or closely associated entities. - The document is a specific transaction report, not a general announcement of a report (RPA) or a miscellaneous filing (RNS). Therefore, the most appropriate classification is Director's Dealing (DIRS).
2023-02-09 Italian
PR PHARMANUTRA SPA - PHN HYPERCAR FERRARI
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by 'PR' in the subject line and the structure) announcing a new sponsorship/partnership between PharmaNutra S.p.A. (via its Cetilar brand) and Ferrari for the Le Mans Hypercar project. This type of announcement, detailing a business relationship, sponsorship, or strategic move, does not fit neatly into the specific financial reporting categories like 10-K, ER, or IR. It is a general corporate announcement. Since it is not a formal regulatory filing (like a Director's Dealing or Major Shareholding Notification) and is more specific than a generic 'Regulatory Filing' (RNS), the best fit among the provided options for a significant, non-financial-results-focused corporate update that isn't covered elsewhere is often the general Regulatory Filing (RNS) if a more specific category like M&A (TAR) or Capital Change (CAP) is inapplicable. However, given the context of corporate news releases that are not earnings or management changes, and since it is a formal communication ('Informazione Regolamentata'), it is a regulatory disclosure. Since there is no specific 'Partnership Announcement' code, and it is not a management change (MANG), dividend (DIV), or financing event (CAP), RNS serves as the appropriate general regulatory disclosure category for this type of news release.
2023-02-08 English
CS PHARMANUTRA SPA - PHN HYPERCAR FERRARI
Regulatory Filings Classification · 1% confidence The document is a press release (indicated by the structure, date, and 'Oggetto' field containing 'CS PHARMANUTRA SPA') announcing a sponsorship agreement between PharmaNutra and Ferrari-AF Corse for the Le Mans Hypercar challenge. It is dated February 8, 2023, and contains general business news and partnership details, not specific periodic financial results (like 10-K, IR, ER, or MRQ). Since it is a general corporate announcement that doesn't fit the specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend Notice (DIV), it falls best under the general Regulatory Filings/Announcements category, which is RNS, as it is a formal communication released via a regulatory channel ('Informazione Regolamentata'). It is not an announcement *about* a report (RPA), but the report itself is a press release detailing a business event.
2023-02-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.